A research centre at the University of Virginia has opened enrolment for its first clinical study, testing a small earpiece that gently stimulates the vagus nerve as a way to ease depression, anxiety and sleep problems in people receiving treatment for addiction.
The Center for Neuromodulation Research, founded in 2025, is running the pilot study. Daisy Thompson-Lake, an assistant professor of psychiatry and neurobehavioral sciences who co-leads the centre, told UVA Today that the study is designed to assess whether the treatment is safe, comfortable and practical for people to use at home, and whether it shows enough promise to justify a larger trial.
The device, provided free of charge by the London-based medical device company Parasym, clips onto the tragus — the small flap at the front of the ear. A branch of the vagus nerve runs close to the skin there, allowing stimulation without surgery. Participants use the device at home for one hour a day for 30 days and attend five study visits. They are compensated for their time.
Thompson-Lake said the study is enrolling adults aged 18 to 60 who are in outpatient treatment for drug use. She noted that depression, anxiety and poor sleep are common among people in recovery and are among the main reasons people struggle to stay in treatment.
The vagus nerve is the main communication line between the brain and the body's organs and is a key part of the body's "rest and digest" system, which balances the "fight or flight" stress response. Thompson-Lake explained that in people with addiction, that stress response is often stuck in overdrive. By gently stimulating the vagus nerve, the aim is to strengthen its calming signal to the brain, telling it, "Everything's fine. We can relax."
Thompson-Lake said vagus nerve stimulation has become "quite trendy" but has a long scientific history. An implanted device placed in the neck was approved by the U.S. Food and Drug Administration for treatment-resistant depression in 2005. That approach requires surgery, but newer technology can reach the vagus nerve through the skin. One ear-based device has already been cleared by the FDA to ease opioid withdrawal symptoms, according to Thompson-Lake.
The Center for Neuromodulation Research was set up when Thompson-Lake and director James Mahoney moved to UVA from West Virginia University last year. At West Virginia, they were part of teams that carried out some of the first studies of focused ultrasound and deep brain stimulation as treatments for addiction.
The centre works in three main areas: low-intensity focused ultrasound, which uses sound waves to reach deep brain regions involved in reward and craving without surgery or tissue damage; vagus nerve stimulation delivered through the ear; and brain imaging using MRI to see how the brain changes with treatment and to choose the best targets.
Thompson-Lake said the move to UVA was "small geographically, but big scientifically," noting that UVA has a long history in focused ultrasound and that the Focused Ultrasound Foundation is based in Charlottesville. She said the centre can now grow from one or two techniques into a full research program with a strong focus on noninvasive treatments that could one day be used outside the hospital, and even at home.
Building the centre required equipment, partnerships, staff and approved study protocols before the first participant could enrol. Thompson-Lake said she approached Parasym and the company agreed to provide devices free of charge. This will be the first time their device has been tested in people being treated for addiction. The centre also worked with UVA's Data Analytics Center to set up a master infrastructure system and MRI pipelines, and with the Mobile AI for People Lab to build a smartphone app for the study. The app reminds participants daily to use the device and asks a few short questions about mood, sleep and craving, allowing researchers to see how people are doing day-to-day, not just during clinic visits.
Anyone interested in the study, or in other centre studies opening soon, can complete a short screening survey, according to UVA Today.